Patent intelligence · US
US 11779660
Viral vectors for cancer therapy
Viral vectors for cancer therapy
Patent details — US 11779660
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 10, 2023
- Expiration
- Oct 5, 2043
- Applicant
- Krystal Biotech, Inc.
- Claims
- 32
- CPC classes
- A61K, A61K35/763, A61K38/193, A61K38/2013
Quick answer
US 11779660 (Viral vectors for cancer therapy) is held by Krystal Biotech, Inc.. Status: granted. Granted Oct 10, 2023. Expires Oct 5, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Krystal Biotech, Inc.
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K35/763, A61K38/193, A61K38/2013, A61K38/208, A61K48/0066
More from Krystal Biotech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364775
Viral vectors for cancer therapy
granted -
US 12128122
Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic
granted -
US 11918660
Viral vectors for cancer therapy
granted -
US 11865148
Methods of delivering transgenes to the eye
granted -
US 11717547
Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
granted -
US 11642384
Compositions and methods for the treatment of Netherton Syndrome
granted -
US 11185564
Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
granted
Frequently asked questions
What is US patent 11779660?
US 11779660 (Viral vectors for cancer therapy) is held by Krystal Biotech, Inc.. Status: granted. Granted Oct 10, 2023. Expires Oct 5, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11779660?
Krystal Biotech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11779660 expire?
Our index shows an expiration date of Oct 5, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.